The Role of Interferon in Hepatitis B Therapy

por Rijckborst, Vincent, Janssen, Harry L. A.
Publicado 2010

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B

por Sonneveld, Milan J., Janssen, Harry L. A.
Publicado 2010

Letter to the Editor: Entecavir Treatment Restores the Anti‐HBV Immune response?

por Beudeker, Boris J.B., Janssen, Harry L.A., Boonstra, Andre
Publicado 2021

Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV

por Vanwolleghem, Thomas, Adomati, Tom, Van Hees, Stijn, Janssen, Harry L.A.
Publicado 2021

Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

por Choi, Hannah S.J., Tonthat, Alexander, Janssen, Harry L.A., Terrault, Norah A.
Publicado 2021

Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response

por Sonneveld, Milan J., Zoutendijk, Roeland, Flink, Hajo J., Zwang, Louwerens, Hansen, Bettina E., Janssen, Harry L. A.
Publicado 2013

The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function

por van der Aa, Evelyn, Buschow, Sonja I., Biesta, Paula J., Janssen, Harry L. A., Woltman, Andrea M.
Publicado 2016

Hepatitis B Virus Lacks Immune Activating Capacity, but Actively Inhibits Plasmacytoid Dendritic Cell Function

por Woltman, Andrea M., Op den Brouw, Marjoleine L., Biesta, Paula J., Shi, Cui C., Janssen, Harry L. A.
Publicado 2011

Monocytes from Chronic HBV Patients React In Vitro to HBsAg and TLR by Producing Cytokines Irrespective of Stage of Disease

por Boltjes, Arjan, Groothuismink, Zwier M., van Oord, Gertine W., Janssen, Harry L. A., Woltman, Andrea M., Boonstra, André
Publicado 2014

Virus–drug interactions—molecular insight into immunosuppression and HCV

por Pan, Qiuwei, Tilanus, Hugo W., Metselaar, Herold J., Janssen, Harry L. A., van der Laan, Luc J. W.
Publicado 2012

Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study

por Tadrous, Mina, Brahmania, Mayur, Martins, Diana, Knowles, Sandra, Janssen, Harry L. A., Mamdani, Muhammad M., Juurlink, David N., Gomes, Tara
Publicado 2018

Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy

por Claassen, Mark A. A., de Knegt, Robert J., Turgut, Duygu, Groothuismink, Zwier M. A., Janssen, Harry L. A., Boonstra, André
Publicado 2012

Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients

por Chua, Conan G., Mehrotra, Aman, Mazzulli, Tony, Wong, David K., Feld, Jordan J., Janssen, Harry L. A., Gehring, Adam J.
Publicado 2020

Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection

por Ferrando-Martinez, Sara, Snell Bennett, Angie, Lino, Elisabete, Gehring, Adam J., Feld, Jordan, Janssen, Harry L. A., Robbins, Scott H.
Publicado 2021

Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection

por Krassenburg, Lisette A P, Zanjir, Wayel R, Georgie, Firas, Stotland, Emily, Janssen, Harry L A, Hansen, Bettina E, Feld, Jordan J
Publicado 2020

Effectiveness of health-related quality-of-life measurement in clinical practice: a prospective, randomized controlled trial in patients with chronic liver disease and their physic...

por Gutteling, Jolie J., Darlington, Anne-Sophie E., Janssen, Harry L. A., Duivenvoorden, Hugo J., Busschbach, Jan J. V., de Man, Robert A.
Publicado 2008

Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection

por Hou, Jun, Brouwer, Willem P., Kreefft, Kim, Gama, Lucio, Price, Sarah L., Janssen, Harry L. A., French, Pim J., Vanwolleghem, Thomas, Boonstra, Andre
Publicado 2017

Elevated serum levels of soluble CD14 in HBeAg‐positive chronic HBV patients upon Peginterferon treatment are associated with treatment response

por Dou, Yingying, van Montfoort, Nadine, van den Bosch, Aniek, Janssen, Harry L. A., de Man, Robert A., Buschow, Sonja I., Woltman, Andrea M.
Publicado 2019

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection

por Ferrando-Martinez, Sara, Huang, Kelly, Bennett, Angie Snell, Sterba, Patricia, Yu, Li, Suzich, JoAnn A., Janssen, Harry L.A., Robbins, Scott H.
Publicado 2019

Combined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing

por Pan, Qiuwei, Henry, Scot D., Metselaar, Herold J., Scholte, Bob, Kwekkeboom, Jaap, Tilanus, Hugo W., Janssen, Harry L. A., van der Laan, Luc J. W.
Publicado 2009